REFERENCES
- Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381–7.
- Patel R, Snydman DR, Rubin RH, Ho M, Pescovitz M, Martin M, Paya CV. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279–89.
- Dickinson I, Gora-Harper ML, McCraney SA, Gosland M. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients. Ann Pharmacother 1996; 30: 1452–64.
- Whitley RJ, Gnann JWJ. Aciclovir: A decade later. New Engl J Med 1992; 327: 782–9.
- Crumpacker CS. Ganciclovir. New Engl J Med 1996; 335: 721–9.
- Birkeland SA, Gahrn-Hansen B, Andersen HMK, Rohr N, Larsen K-E, Jørgensen KA. CMV-prophylaxis in antibody treated renal transplanted patients. Transplant Proceed 1995; 27: 3473–6.
- Birkeland SA, Elbirk A, Rohr N, Jørgensen KA. Optimization of cyclosporin monotherapy. Transplant Proceed 1994; 26: 2501–6.
- Birkeland SA, Elbirk A, Rohr N, Jørgensen KA. Cyclosporin monotherapy in children: Long-term effect. Transplant Proc 1994; 26: 2610–6.
- Birkeland SA. Steroid-free immunosuppression in renal transplantation (Letter). Lancet 1996; 348: 1105–6.
- Birkeland SA. Mycophenolate mofetil to rescue children with acute renal transplant rejection. Lancet 1996; 347: 1699–700.
- Birkeland SA, Larsen KE, Rohr N. Pediatric renal transplantation without steroids. Pediatr Nephrol 1998; 12: 87–92.
- Nielsen SL, Sørensen, I, Andersen HK. Kinetics of specific immunoglobulins M, E, A, and G in congenital, primary and secondary cytomegalovirus infection studied by antibody capture ELISA. J Clin Microbiol 1988; 26: 654–61.
- Farrugia E, Schwab TR. Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin Proc 1992; 67: 879–90.
- Snydman DR, Rubin RH, Werner BG. New developments in cytomegalovirus prevention and management. Am J Kidney Dis 1993; 21: 217–28.
- Ho¨keberg I, Eriksson BM, Zweygberg-Wirgart B, Tufvesson G, Olding-Stenkvist E, Lena Grillner L. Diagnostic markers and risk factors of cytomegalovirus infection and disease in renal allograft recipients. Scan J Infect Dis 1995; 27: 435–40.
- Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 358: 162–4.
- Kletzmayer J, Kotzman H, Popow-Kraupp T, Kowarik J, Klauser R. Impact of high dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996; 7: 325–30.
- Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, et al. Prophylaxis of cytomegalovirus infection in liver transplantation. Transplantation 1997; 64: 66–73.
- Conti DJ, Freed BM, Singh TP, Gallichio M, Gruber SA, Lempert N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplant patients. Arch Surg 1995; 130: 1217–22.
- Martin M, Snydman DR. How effective is oral ganciclovir. Transplant Proc 1996; 28 Suppl 2: 14–5.
- Meyer T, Scholz D, Warnecke G, Kunz M, Arndt R, Reischl U, Wolf H, Lissner R. Importance of simultaneous active cytomegalovirus and Epstein-Barr virus infection in renal transplantation. Clin Diagn Virol 1996; 6: 79–91.
- Balfour HHJ. Prevention of cytomegalovirus disease. Int J Antimicrobiol Agents 1996.
- Griffiths PD. Prophylaxis against CMV infection in transplant patients. J Antimicrobiol Chemother 1997; 39: 299–301.